Farxiga and Finasteride Interaction: Safety, Risks, and Clinical Guidance

The direct answer

There is no known pharmacokinetic or pharmacodynamic drug-drug interaction between dapagliflozin and finasteride established in the current FDA prescribing information for either drug. Dapagliflozin is cleared mainly by UGT1A9-mediated glucuronidation and is not a meaningful CYP3A4 substrate, inhibitor, or inducer; finasteride is cleared mainly by CYP3A4. Because the two drugs do not share a metabolic bottleneck or a transporter, co-administration would not be expected to change either drug's blood levels, and neither manufacturer's label lists the other as a co-medication of concern as of the labels reviewed for this page.

That is a plausibility-based conclusion built on how each drug is metabolized, not a conclusion drawn from a dedicated interaction trial of the two drugs together. No such trial appears to exist in the public record, which is common for combinations of two widely used but mechanistically unrelated drugs.

Why these two drugs end up prescribed together

Type 2 diabetes is common in the same age group that develops benign prostatic hyperplasia (BPH), so a man in his 50s or 60s may reasonably be on an SGLT2 inhibitor for glucose, heart failure, or kidney protection while also taking finasteride for prostate symptoms or, at the lower dose, for hair loss. The overlap is about shared patient demographics, not a pharmacologic reason to combine the drugs.

What is established about the metabolic pathways

Dapagliflozin's clearance is dominated by phase II glucuronidation via UGT1A9, producing an inactive metabolite, with minimal reliance on cytochrome P450 enzymes. This is described in current Farxiga prescribing information.

Finasteride is absorbed orally and metabolized primarily through hepatic CYP3A4, as described in current finasteride (Proscar) prescribing information.

Because dapagliflozin is not a CYP3A4 inhibitor or inducer, it would not be expected to raise or lower finasteride levels. Because finasteride does not act on UGT1A9 or on the transporters dapagliflozin uses, it would not be expected to change dapagliflozin exposure. This is the pharmacologic basis for saying the combination is "clean," but it is a mechanism-based inference rather than a result confirmed by a dedicated co-administration study, and a reviewing clinician or pharmacist should verify against current Lexicomp or Micromedex interaction entries before relying on it for an individual patient.

Pharmacodynamic overlaps that can confuse symptom tracking

The two drugs do not interact chemically, but their side-effect profiles can overlap in ways that matter for how a patient and clinician interpret new symptoms.

Genital and sexual symptoms. Finasteride's mechanism, suppressing dihydrotestosterone (DHT), is the documented cause of its sexual side effects, which include reduced libido, erectile difficulty, and decreased ejaculate volume in a meaningful minority of users; the exact incidence figures vary across trials and should be checked against the current label rather than quoted as a fixed number here. Dapagliflozin's genital risk is unrelated hormonally: SGLT2 inhibition increases urinary glucose, which raises the risk of genital mycotic (yeast) infections, and the FDA has separately warned about a rare but serious necrotizing genital infection (Fournier's gangrene) associated with the SGLT2 inhibitor class. The FDA has separately issued a drug safety communication on rare serious genital infections associated with SGLT2 inhibitors. A patient reporting genital discomfort while on both drugs needs clinical evaluation to determine which mechanism, if either, is responsible; the two causes require different responses (finasteride dose reconsideration versus antifungal treatment or urgent evaluation for a spreading genital infection).

Blood pressure and volume status. Dapagliflozin causes mild osmotic diuresis and a modest blood pressure reduction as a class effect of SGLT2 inhibition. Finasteride has no direct hemodynamic effect, so the two drugs alone do not create an additive hypotension risk. The relevant three-drug concern is dapagliflozin plus an alpha-blocker such as tamsulosin, which many BPH patients also take; that combination can plausibly compound orthostatic symptoms, and it is worth reviewing the full medication list rather than assuming finasteride itself is the contributing factor.

Evidence-status assessment: what's known, what's plausible, what needs verification

Renal function: a monitoring parameter both drugs touch, for different reasons

Dapagliflozin's benefit for kidney protection and its labeled dosing depend on a patient's eGFR, and SGLT2 inhibitors are known to produce an early, expected dip in eGFR after initiation that generally reflects a hemodynamic adjustment rather than kidney injury, per current FDA labeling and diabetes care guidelines. Finasteride is metabolized hepatically, and its label does not require a dose adjustment based on renal function, though clearance of its metabolites is partly renal.

The practical implication: a periodic eGFR check makes sense for a patient on dapagliflozin regardless of finasteride use. If renal function changes, the clinical response should center on the dapagliflozin regimen and the patient's underlying kidney disease or heart failure status, not on finasteride dosing.

Hematocrit: a dapagliflozin-specific consideration, especially with testosterone therapy

Dapagliflozin, as an SGLT2 inhibitor, is associated with a rise in hematocrit, thought to reflect increased erythropoietin activity related to reduced renal cortical oxygen demand. Finasteride itself has no known effect on red blood cell production. The relevant drug interaction concern is with a third agent, not finasteride: patients on finasteride for BPH who are also receiving testosterone replacement therapy face an independent erythrocytosis risk. When dapagliflozin is added to this finasteride-plus-testosterone combination, a baseline and periodic hematocrit check is a reasonable precaution. The exact magnitude of dapagliflozin's hematocrit effect varies across published reports and should be confirmed against the current label rather than quoted as a fixed percentage.

Euglycemic DKA: a class risk of dapagliflozin, unaffected by finasteride

Euglycemic diabetic ketoacidosis is a recognized, uncommon risk of SGLT2 inhibitors, in which ketoacidosis develops despite near-normal glucose readings. Finasteride has no known effect on ketone metabolism, insulin secretion, or glucose handling, so it does not add to or subtract from this risk. Standard precautions apply regardless of finasteride use: patients should be counseled to report unexplained nausea, vomiting, or abdominal pain, and clinicians typically hold SGLT2 inhibitors before planned surgery per current labeling and institutional protocols. Confirm the current recommended peri-operative hold interval against the drug label rather than assuming a fixed number of days.

PSA monitoring: a finasteride-specific issue that dapagliflozin does not change

Finasteride is known to lower serum PSA over the course of treatment, which is why urology guidance recommends applying a correction factor when interpreting PSA values in men on the drug, to avoid missing a clinically meaningful rise that would otherwise be masked. Dapagliflozin has no known effect on PSA. This monitoring point belongs entirely to the finasteride side of the regimen: a baseline PSA before starting finasteride, and application of the guideline-recommended correction factor at subsequent screenings, is the standard approach. The exact correction factor and its evidentiary basis should be pulled from a current urology guideline document rather than repeated from memory, since recommendations have been updated over time.

A practical way to think about co-prescribing

No dose adjustment is indicated for either drug on the basis of this combination alone. Because the two drugs do not compete for absorption or metabolism, timing separation between doses is not required.

A reasonable baseline-and-follow-up framework, to be adapted by the prescribing clinician:

• Baseline labs before starting either drug: eGFR, HbA1c (if diabetic), hematocrit, PSA (if starting finasteride), and a basic hepatic panel.
• Follow-up eGFR and HbA1c around 3 months after starting or adjusting dapagliflozin.
• Hematocrit recheck if the patient is also on testosterone therapy, or if there is a personal history of erythrocytosis.
• PSA recheck at the interval recommended by current urology guidance, applying the correction factor for finasteride use.
• Ongoing counseling: genital discomfort should prompt evaluation rather than assumption about which drug is responsible; sexual side effects are more consistent with finasteride's mechanism; dizziness on standing should trigger a full medication review, especially if an alpha-blocker or other blood pressure-lowering drug is also present.

Evidence boundary

Established: dapagliflozin and finasteride are metabolized through different pathways (UGT1A9 glucuronidation versus CYP3A4), and neither current FDA label flags the other drug as an interaction concern.

Plausible but not confirmed by a dedicated trial: that the absence of a shared pathway translates into zero clinically meaningful interaction in every patient, since no publicly available head-to-head interaction study of the two drugs appears to exist.

Not established: any claim that finasteride worsens or improves a dapagliflozin-specific risk (genital infection, euglycemic DKA, hematocrit rise), or that dapagliflozin changes finasteride's effect on DHT or PSA. Any precise percentage attached to these individual drug effects should be verified against the current FDA label or a current guideline document before being used in patient counseling, since figures drawn from secondary summaries can be outdated or mismatched to the wrong trial.

When to seek urgent care regardless of this interaction question: sudden genital swelling, redness, or pain that spreads quickly (possible necrotizing infection), unexplained nausea and abdominal pain with fatigue (possible ketoacidosis even with normal-seeming glucose), or fainting or severe dizziness on standing.